Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2015 May 12;14(7):1717–1727. doi: 10.1158/1535-7163.MCT-14-0607

Figure 4. TG101209 treatment in Apc−; Pten−; Trp53− mice improves survival and reduces metastasis.

Figure 4

(Ai) Timeline of cisplatin and TG101209 administration and (ii) Survival curves for mice treated with cisplatin (2mg/Kg once per week × 2 weeks) vs cisplatin + TG101209 (50mg/kg daily for 21 days) p=0.04 (n=12 total combined results from two (n=6) independent experiments). (Bi) Timeline of TG101209 treatment and (ii) survival curves of mice treated with control (DMSO, n=9) and TG101209 (n=14) combined results from three independent experiments. (C) Evaluation of metastases in mice demonstrates significant reduction in the number of (i) macroscopic metastatic tumor nodules and metastatic tumor volume. C (ii and iii) images of metastatic nodules and histologic confirmation of metastases; red arrows indicate metastasis while blue arrow indicates primary ovarian tumor. (D) Representative IHC and quantification of p-STAT3 stain in control TG101209 treated tumors. ** indicates p<0.01.